Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 8, 2015, Pages 768-775

  Gisbert, J P ^a   Romano, M ^b   Gravina, A G ^c   Solis Munoz P ^d   Bermejo, F ^e   Molina Infante, J ^f   Castro Fernandez M ^g,h   Ortuno J ^h,i   Lucendo, A J ^j   Herranz, M ^k   Modolell, I ^l   Del Castillo, F ^m   Gomez J ⁿ   Barrio, J ^o   Velayos, B ^p   Gomez B ^q   Dominguez J L ^r   Miranda, A ^b   Martorano, M ^c   Algaba, A ^e   Pabon M ^g,h   Angueira, T ^j   Fernandez Salazar L ^p   Federico, A ^b   Marin A C ^a   McNicholl, A G ^a   more..

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Ospedale PO della Immacolata   (Italy)

^d Angloamerican Medical Unit Gastroenterology and Hepatology   (Spain)

^e HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^f HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

^g HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^h INSTITUTO DE SALUD CARLOS III   (Spain)

ⁱ HOSPITAL UNIVERSITARIO LA FE   (Spain)

^j HOSPITAL GENERAL DE TOMELLOSO   (Spain)

^k HOSPITAL NUESTRA SEÑORA DE SONSOLES   (Spain)

^l Brain   (Spain)

^m Hospital Don Benito   (Spain)

ⁿ HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^o HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^p HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^q HOSPITAL QUIRÓN   (Spain)

^r Alto Guadalquivir Hospital   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; ESOMEPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; ANTACID AGENT; ANTIDIARRHEAL AGENT; ANTIINFECTIVE AGENT; BISMUTH; PROTON PUMP INHIBITOR; UREA;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC THERAPY; ARTICLE; ASTHENIA; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ERADICATION THERAPY; EVENING DOSAGE; FEMALE; HELICOBACTER INFECTION; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; METALLIC TASTE; MIDDLE AGED; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT DURATION; VOMITING; AGED; BREATH ANALYSIS; CLINICAL TRIAL; DRUG COMBINATION; HELICOBACTER INFECTIONS; PROSPECTIVE STUDY;

ADULT; AGED; AMOXICILLIN; ANTACIDS; ANTI-BACTERIAL AGENTS; ANTIDIARRHEALS; BISMUTH; BREATH TESTS; DRUG THERAPY, COMBINATION; ESOMEPRAZOLE; FEMALE; HELICOBACTER INFECTIONS; HUMANS; LEVOFLOXACIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; UREA;

EID: 84924975853     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13128     Document Type: Article

References (52)

1. Graham DY, Fischbach L,. Helicobacter pylori infection. N Engl J Med 2010; 363: 595-6; author reply 6.
2. Malfertheiner P, Megraud F, O'Morain CA, et al,. Management of Helicobacter pylori infection-the Maastricht IV/Florence consensus report. Gut 2012; 61: 646-64.
3. Gisbert JP, Calvet X,. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther 2011; 34: 1255-68.
4. Megraud F, Coenen S, Versporten A, et al,. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 12: 34-42.
5. Gisbert JP, Calvet X, O'Connor A, Megraud F, O'Morain CA,. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010; 44: 313-25.
6. Gisbert JP, Calvet X,. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 2012; 5: 23-34.
7. Gisbert JP, Pajares JM,. Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002; 16: 1047-57.
8. Gisbert JP,. "Rescue" regimens after Helicobacter pylori treatment failure. World J Gastroenterol 2008; 14: 5385-402.
9. Gisbert JP, Morena F,. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006; 23: 35-44.
10. Saad RJ, Schoenfeld P, Kim HM, Chey WD,. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006; 101: 488-96.
11. Li Y, Huang X, Yao L, Shi R, Zhang G,. Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. Wien Klin Wochenschr 2010; 122: 413-22.
12. Gisbert JP, Perez-Aisa A, Bermejo F, et al,. Second-line therapy with levofloxacin after failure of treatment to eradicate Helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients. J Clin Gastroenterol 2013; 47: 130-5.
13. Gisbert JP, Bermejo F, Castro-Fernandez M, et al,. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am J Gastroenterol 2008; 103: 71-6.
14. Manfredi M, Bizzarri B, De'angelis GL,. Helicobacter pylori infection: sequential therapy followed by levofloxacin-containing triple therapy provides a good cumulative eradication rate. Helicobacter 2012; 17: 246-53.
15. Zullo A, de Francesco V, Manes G, Scaccianoce G, Cristofari F, Hassan C,. Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice. J Gastrointest Liver Dis 2010; 19: 131-4.
16. Graham DY, Lu H, Yamaoka Y,. A report card to grade Helicobacter pylori therapy. Helicobacter 2007; 12: 275-8.
17. Chuah SK, Tai WC, Hsu PI, et al,. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment-a pilot study. Helicobacter 2012; 17: 374-81.
18. di Caro S, Franceschi F, Mariani A, et al,. Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication. Dig Liver Dis 2009; 41: 480-5.
19. Malfertheiner P,. Infection: Bismuth improves PPI-based triple therapy for H. pylori eradication. Nat Rev Gastroenterol Hepatol 2010; 7: 538-9.
20. Liao J, Zheng Q, Liang X, et al,. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter 2013; 18: 373-7.
21. Gisbert JP, Badia X, Roset M, Pajares JM,. The TETRA study: a prospective evaluation of Helicobacter pylori 'test-and-treat' strategy on 736 patients in clinical practice. Helicobacter 2004; 9: 28-38.
22. Bago P, Vcev A, Tomic M, Rozankovic M, Marusic M, Bago J,. High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. Wien Klin Wochenschr 2007; 119: 372-8.
23. Gao XZ, Qiao XL, Song WC, Wang XF, Liu F,. Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication. World J Gastroenterol 2010; 16: 4357-62.
24. Hsu PI, Wu DC, Chen A, et al,. Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures. Eur J Clin Invest 2008; 38: 404-9.
25. Yee YK, Cheung TK, Chu KM, et al,. Clinical trial: levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2007; 26: 1063-7.
26. Perna F, Zullo A, Ricci C, Hassan C, Morini S, Vaira D,. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis 2007; 39: 1001-5.
27. Pontone S, Standoli M, Angelini R, Pontone P,. Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice. Dig Liver Dis 2010; 42: 541-3.
28. Zullo A, de Francesco V, Hassan C,. Second-line treatment for Helicobacter pylori eradication after sequential therapy failure: a pilot study. Therapy 2006; 3: 251-4.
29. Gisbert JP, Molina-Infante J, Marin AC, Vinagre G, Barrio J, McNicholl AG,. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection. Scand J Gastroenterol 2013; 48: 652-6.
30. Marín AC, McNicholl AG, Gisbert JP,. Efficacy of a second-line levofloxacin-containing triple therapy after the failure of the non-bismuth sequential or concomitant treatments: systematic review and meta-analysis. Helicobacter 2014; 19 (Suppl. 1): 139.
31. Ciccaglione AF, Cellini L, Grossi L, Marzio L,. Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pylori. World J Gastroenterol 2012; 18: 4386-90.
32. Goodwin CS, Marshall BJ, Blincow ED, Wilson DH, Blackbourn S, Phillips M,. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J Clin Pathol 1988; 41: 207-10.
33. Megraud F,. The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy. Therap Adv Gastroenterol 2012; 5: 103-9.
34. Wagstaff AJ, Benfield P, Monk JP,. Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. Drugs 1988; 36: 132-57.
35. van Caekenberghe DL, Breyssens J,. In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori). Antimicrob Agents Chemother 1987; 31: 1429-30.
36. Gao W, Cheng H, Hu F, et al,. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China. Helicobacter 2010; 15: 460-6.
37. De Francesco V, Giorgio F, Hassan C, et al,. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointest Liver Dis 2010; 19: 409-14.
38. Pérez-Trallero E, Ramírez-Lázaro MJ, Villar H, et al,. Resistencia de Helicobacter pylori a diversos antibiõticos: un estudio multicéntrico español. Gastroenterol Hepatol 2011; 34: 236.
39. Romano M, Cuomo A, Gravina AG, et al,. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut 2010; 59: 1465-70.
40. Federico A, Nardone G, Gravina AG, et al,. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology 2012 143: 55-61 e1; quize e13-4.
41. Graham DY, Shiotani A,. Which therapy for Helicobacter pylori infection? Gastroenterology 2012; 143: 10-2.
42. Ercin CN, Uygun A, Toros AB, et al,. Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia. Turk J Gastroenterol 2010; 21: 12-6.
43. Tai WC, Chuah SK, Wu KL,. The efficacy of second-line anti-Helicobacter pylori eradication using 10-day and 14-day levofloxacin-containing triple therapy. United Eur Gastroenterol J 2013; 1: A5.
44. Lu H, Zhang W, Graham DY,. Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. Eur J Gastroenterol Hepatol 2013; 25: 1134-40.
45. Villoria A,. Acid-related diseases: are higher doses of proton pump inhibitors more effective in the treatment of Helicobacter pylori infection? Gastroenterol Hepatol 2008; 31: 546-7.
46. McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP,. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 36: 414-25.
47. Hillemand P, Palliere M, Laquais B, Bouvet P,. Bismuth treatment and blood bismuth levels. Sem Hop 1977; 53: 1663-9.
48. Ford AC, Malfertheiner P, Giguere M, Santana J, Khan M, Moayyedi P,. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol 2008; 14: 7361-70.
49. Furuta T, Graham DY,. Pharmacologic aspects of eradication therapy for Helicobacter pylori infection. Gastroenterol Clin North Am 2010; 39: 465-80.
50. Liang X, Xu X, Zheng Q, et al,. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol 2013; 11: 802-7 e1.
51. Dore MP, Farina V, Cuccu M, Mameli L, Massarelli G, Graham DY,. Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days. Helicobacter 2011; 16: 295-300.
52. Dore MP, Graham DY, Mele R, et al,. Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection. Am J Gastroenterol 2002; 97: 857-60.